Recently, the Category 1 innovative drug Vorolanib Tablets (Chinese trade name: 伏美纳) of Betta Pharmaceuticals Co., Ltd is approved by China NMPA. It is used in combination with everolimus, indicated for the treatment of patients with advanced renal cell carcinoma who have previously receive tyrosine kinase inhibitor treatment but failed.

Voronib is a multi-kinase inhibitor, which has strong inhibitory effects on VEGFR2, KIT, PDGFR, FLT3 and RET, and exerts anti-tumor effect mainly by inhibiting the formation of new blood vessels. The marketing of this drug provides new treatment options for patients with advanced renal cell carcinoma.